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549 
FDA REGULATORY REQUIREMENTS AS 
TORT STANDARDS 
Richard Merrill* 
INTRODUCTION 
There are essentially two contexts in which laws encounter 
agency-produced and agency-analyzed science. One is in the 
context of reviewing regulatory decisions—a context governed at 
the federal level by the Administrative Procedure Act, at the state 
level by state administrative procedure acts, and sometimes by 
specific statutes that authorize domestic regulatory activity. 
Appellate judges may encounter, and federal judges surely do 
encounter, cases in which a party is petitioning for direct review of 
an agency science-based decision. Trial judges however, are much 
more likely to encounter agency-assessed science in a second 
context—private litigation in which the work of a regulatory body 
is claimed to be either irrelevant, or highly pertinent, to the 
disposition of the case. Therefore, this paper will focus on 
regulation of products that often give rise to claims for civil 
liability. 
In confronting such claims, judges and juries address many 
complicated scientific questions bearing on whether a product is 
capable of causing the kind of harm that the plaintiff experienced 
and whether the use of or exposure to the product caused the harm 
that the particular plaintiff is suffering from. 
Beyond causation, there are also questions about whether the 
manufacturer or discharger of the product took the precautions that 
were necessary to minimize or reduce the risk associated with its 
                                                          
 * A.B., M.A., LL.B.; Daniel Caplain Professor of Law at the University of 
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production or use. This is the question of breach of duty. This 
inquiry has two dimensions—what precautions were in fact taken, 
and what precautions did the responsible regulatory agency require 
to be taken to minimize the risks. These questions—involving 
knowledge about risk and measures taken to avoid risk—are as 
important as the questions about causation. 
Most of the products that give rise to tort claims in today’s 
America are at least potentially regulable by some federal agency, 
sometimes by both a federal and counterpart state regulatory 
agency. But these targets of litigation are not all subject to the 
same level or type of regulation, as can be seen with both the Food 
& Drug Administration (FDA) and Environmental Protection 
Agency (EPA).1 These two agencies are possibly the most 
important public health regulatory agencies operating in 
Washington. The FDA has been in business for ninety-eight years.2 
The EPA’s experience is much briefer but it is surely the most 
science-dependent regulatory agency in Washington. Most of the 
products or pollutants that give rise to civil claims today fall within 
the jurisdiction of one of these two agencies. 
My immediate aims are quite modest. I hope, first, to get you 
to think about how the duty that the civil justice system might 
impose upon product manufacturers or pollutant dischargers 
should be looked at in light of the regulatory requirements the 
manufacturer or the discharger was subject to. Second, I want to 
demonstrate that regulatory systems are not all the same in their 
expectation for care-taking. 
The horn book law in this area of civil liability is 
straightforward. We all remember it from our torts class. Violation 
of a regulatory standard is negligence (or some form of “fault”) per 
se in almost every jurisdiction in the United States.3 If the 
                                                          
1 See Michael A. Friedman, M.D., What Is the Value of an FDA Approval 
in a Judicial Matter?, 12 J.L. & POL’Y 559 (2004); Robert S. Sussman, Science 
and EPA Decision-Making, 12 J.L. & POL’Y 573 (2004). 
2 21 U.S.C. §§ 1-3 (2003). The FDA was empowered by the Food and 
Drugs Act of 1906, which was supplanted by the Federal Food, Drug and 
Cosmetics Act of 1938. 
3 AARON D. TWERSKI, JAMES A. HENDERSON, TORTS: CASES AND 
MATERIALS (Aspen Law & Business 2003). 
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defendant failed to take precautions that a regulatory agency 
required, this will usually end the inquiry into whether the 
defendant fulfilled its civil law responsibility. There is a 
counterpart proposition of narrower reach, namely that compliance 
with regulatory requirements is admissible as evidence of due care, 
but it is not conclusive.4 These companion propositions assume, 
and many cases say, that regulatory standards are minimum 
standards, i.e., the least that the legal system is entitled to expect, 
but not necessarily all that the legal system is entitled to expect. 
Roughly a decade ago the American Law Institute (ALI) 
undertook a study of product and process injuries.5 This was not a 
“Restatement” exercise, but the resulting report purported to be a 
synthesis and critique of legal developments in an arena now come 
to be known as product liability or toxic torts. The project was 
headed by some of the ablest scholars now working in the United 
States, including Robert Rabin of Stanford Law School, and 
Richard Stewart, now of New York University.6 The report they 
produced for the ALI suggested that in some circumstances, most 
pertinently in suits involving FDA-approved prescription drugs, 
regulatory requirements should be understood as the authoritative 
assessment of the benefits and risks of a product and express the 
legal system agency’s authoritative judgment about how best to 
minimize those risks. If the agency had access to all of the 
evidence about the product’s risks that was later available in a 
lawsuit, a holding that the manufacturer should have taken 
additional precautions would create conflict between the common 
law tort system, on the one hand, and the regulatory system that 
Congress has established for guarding against and minimizing 
product and process injuries.7 
                                                          
4 Id. 
5 AM. LAW INST., REPORTERS’ STUDY ON ENTERPRISE RESPONSIBILITY FOR 
PERSONAL INJURY (1991) (the Project on Compensation and Liability for 
Product and Process Injuries, later renamed the Project on Enterprise 
Responsibility for Personal Injury). 
6 Id. See also Robert Rabin, Reassessing Regulatory Compliance, 88 GEO. 
L. J. 2049 (2000); Richard B. Stewart, Regulatory Compliance Preclusion of 
Tort Liability: Limiting the Dual-Track System, 88 GEO. L. J. 2167 (2000). 
7 AM. LAW INST., supra note 5. 
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The immediate question is: Do those observations have any 
relevance in the context of the work that FDA does today? 
The FDA administers one basic statute: the Federal Food, Drug 
and Cosmetic Act, enacted in 1938.8 It has been amended 
numerous times since then to expand the regulatory expectations 
for products under FDA’s aegis, but these amendments have not 
fundamentally changed the scope of the agency’s regulatory 
responsibilities. Those responsibilities are framed by five product 
categories for which the regulatory system has very different kinds 
of expectations. 
The five product categories are cosmetics, food, therapeutic 
drugs, medical devices, and, finally, dietary supplements, a fifth 
category created by statute in 1994.9 These five categories 
encompass many of the products that give rise to civil lawsuits in 
the United States today. Drugs and medical devices lead the list. 
We do not have many tort claims challenging the safety of food 
substances and relatively few involving the safety of cosmetics. 
The descriptions that follow are general. They do not take 
account of the possibility that in a particular case the basic 
requirements I have ascribed to FDA may not have been omitted or 
might have been added to. 
1. Cosmetics 
In regulating cosmetics, the agency functions like a highway 
patrolman. Its inspectors look out for products that are dangerous 
to health, about which it can, like a highway patrol man, do 
something. That something is to initiate administrative or judicial 
enforcement action on the premise that the product is not as safe as 
the law expects it to be, or that the product is not labeled as the law 
expects it to be labeled.10 
In a nutshell, what the law says to a cosmetics manufacturer is: 
“Don’t injure and don’t mislead buyers of your products.” The law 
                                                          
8 21 U.S.C. §§ 1-3 (1938). 
9 21 U.S.C. § 301 (1997). 
10 PETER BARTON HUTT & RICHARD A. MERRILL, FOOD & DRUG LAW: 
CASES & MATERIALS (2d ed. 1991). 
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FDA administers imposes no obligation on cosmetic manufacturers 
to do any testing of the products. Of course, manufacturers 
routinely do testing, but that is not because FDA demands it. Nor 
does the law give FDA any authority to evaluate the results of the 
manufacturer’s testing before the product goes on the market. FDA 
regulation of cosmetics is entirely ex post. 
2. Food 
With an important exception, each of the foregoing statements 
about FDA’s regulation of cosmetics describes its regulation of 
food. A seller of food may put it on the market, after whatever 
testing it believes it prudent to do, without ever contacting FDA. 
The law says that food can not harm consumers and FDA may take 
measures after the fact to curtail the marketing of food that it 
believes harmful. FDA’s labeling requirements for food are more 
elaborate than for cosmetics, but they too can be summarized as 
saying: “Don’t mislead and don’t lie about the composition or 
utility of your product.” 
Again, in regulating foods substances, FDA functions like a 
highway patrol officer. The agency devoted substantial resources 
to this activity. Hundreds of FDA inspectors are engaged in 
investigating food establishments. They occasionally visit grocery 
stores. They follow up reports of food poisoning and the like. But 
FDA does not have authority to require pre-market approval for 
food products. 
The notable exception is for new food ingredients, which under 
the law are defined as “food additives.” Imagine someone who 
hopes to develop and market a new non-nutritive sweetener—
something lower in calories than sugar, perhaps with other useful 
traits. The FDEC Act requires that the developer of this sweetener 
go to FDA and secure agency approval of its safety.11 Utility is left 
to the marketplace, but safety is the FDA’s judgment. It is a 
judgment made in advance of the introduction of any new food 
ingredient. 
However, for reasons that will be obvious on a moment’s 
                                                          
11 21 U.S.C. § 349 (2003). 
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reflection, the FDA’s safety judgment will not ordinarily be based 
on human evidence. It is generally considered unethical to conduct 
experiments of a new chemical in human subjects unless the 
chemical offers some therapeutic benefit. Thus, while we do test 
drugs in human subjects we do not test food additives in human 
beings before they enter the marketplace. 
The law requires the sweetener inventor to conduct elaborate 
long-term animal feeding experiments designed to explore possible 
ways in which the substance might be harmful to human beings.12 
The FDA may then restrict the level or frequency of its use, 
extrapolating from the results in laboratory animals. 
3. Therapeutic Drugs 
My third category is therapeutic drugs. The law’s requirements 
for drugs are quite different than those for cosmetics and food—
and the differences should matter to judges. 
All new drugs require FDA approval for safety and 
effectiveness before they may be marketed. Since all drugs have 
side effects—some rare, some mild, some frequent—that need to 
be guarded against, a central feature of FDA approval is the label, 
with its instructions and warnings, that the agency prescribes at the 
time that it approves the product. 
When FDA approves a new drug for marketing, it is making a 
judgment about relative benefit and risk, and it mandates the 
instructions—conventionally directed to the physician, not to the 
patient—about measures necessary to minimize risks and 
maximize benefits. The agency’s approval of a drug represents a 
judgment that the product, when used in accordance with the label 
instructions, is reasonably safe, taking into account its medical 
benefit. 
In contrast with its approval of a food additive, FDA approval 
of a drug is based on randomized clinical trials in human beings. 
Such trials may extend over months or even years. Perhaps as 
many as 5,000, possibly even 10,000, patients will have been 
exposed to the drug and their experience analyzed before the FDA 
                                                          
12 Id. 
MERRILLMACRO.DOC 4/23/2004  12:52 PM 
 FDA REGULATION AND TORT LITIGATION 555 
is prepared to judge the drug safe and effective. The results of 
these clinical studies are carefully reviewed by the agency, and 
their design and conduct are often reviewed in advance.13 
FDA can revise the terms of its initial approval of a drug by 
requiring changes in the labeling or, less often, in the composition 
of the product. Manufacturers must submit to FDA information 
that they receive about experience with the drug that suggests the 
risks are greater or different than originally anticipated. The legal 
duty to report adverse events applies only to manufacturers, but 
information about post-approval experience also comes to the FDA 
from physicians, health care providers, and not infrequently from 
public health authorities in other countries. In short, FDA 
regulation of drugs involves a kind of ongoing oversight that is not 
true of cosmetics or foods, or even food additives. 
Over-the-counter (OTC) drugs could be thought of as a special 
case. However, most of the non-prescriptions drugs that have been 
introduced in the last fifteen years first came onto the market 
through the FDA approval process for prescription drugs.14 
4. Medical Devices 
Medical devices, which give rise to civil claims with some 
frequency, are subject to a different set of regulating requirements 
than applies to drugs. The FDEC Act’s requirements for devices 
were dramatically expended in 1976.15 The differences between 
the requirements for devices and these for drugs potentially have 
implications for the civil liability system. 
There are two pathways by which a new medical device can 
come onto the marketplace. One looks very much like the process 
by which a new prescription drug gains FDA approval. Approval 
requires a finding that the device is safe and effective—or, more 
accurately, provides benefits that outweigh its risks. FDA approval 
is based on the results of clinical trials in randomized human 
subjects, whose data are submitted to, and closely evaluated by, 
                                                          
13 See Friedman, supra note 1. 
14 HUTT & MERRILL, supra note 10. 
15 21 U.S.C. § 321(h) (2003). 
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FDA. For example, a new implant of almost any sort is likely to 
have gone through this premarket approval (PMA) process. 
But the law requires another pathway to the market for devices 
that represent modest advances on the existing technology. For 
such devices the law affords a less rigorous path to the market, 
known as the 510K or pre-market notification process. To follow 
this pathway the maker must give the FDA advance notice of its 
plan to market the product and demonstrate, not that the product is 
safe and effective based on clinical studies, but that it is 
“substantially equivalent” to an existing device. This is a 
significantly less rigorous burden than required by the PMA 
process. 
Several years ago, in Medtronic, Inc. v. Lohr, Justice Stevens 
provided a lucid description of these two statutory pathways and 
emphasized how they differ with respect to the question of whether 
compliance with FDA’s requirements should afford a defense to 
tort liability.16 The Medtronic case arose because the medical 
device law, uniquely, contains a feature of special relevance to our 
inquiry: Congress included a pre-emption provision in 1976 device 
amendments.17 The provision states that no state may impose 
requirements that are different from or in addition to the 
requirements FDA has imposed to assure the safety of a device.18 
The possibility that a tort verdict could be viewed as a 
“requirement” that adds to FDA requirements has been the focus of 
several dozen cases, mainly in the federal courts.19 Because most 
medical devices have entered the market through the 510k 
“substantially equivalent” pathway, they have received less 
scrutiny from FDA than most therapeutic drugs. 
5. Dietary Supplements 
Dietary supplements are products that appeal to consumers 
who desire their promised physical effects, but typically avoid 
                                                          
16 Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996). 
17 Id. at 470; 21 U.S.C. § 360k(a) (2003). 
18 21 U.S.C. § 360k(a). 
19 Caraker v. Sandoz Pharm. Corp., 172 F. Supp. 2d 1018 (S.D. Ill. 2001). 
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overt claims about their health benefits. They are not promoted as 
medicines. In 1994 Congress, for only the second time in the 
agency’s history, amended the law to relax FDA’s regulatory 
oversight category of products, which it called “dietary 
supplements.” 20 
As a result of this legislation FDA has no authority to require 
evidence of safety for any dietary supplement. Whatever testing of 
these products is done, is done voluntarily by the manufacturer. 
Like manufacturers of cosmetics and ordinary foods, the maker of 
a dietary supplement cannot lie about the product. The FDA must 
be notified if the manufacturer intends to market a dietary 
ingredient that has never before been used in the United States. 
However, this is simply a mechanism for alerting the agency so it 
can invoke its ex post authority to punish misleading labeling or 
harmful products. It does not provide FDA an opportunity to exert 
ex ante controls. 
CONCLUSION 
The primary message of this short essay is easily summarized. 
In deciding what, if any, weight to accord, in a tort suit, evidence 
that a product manufacturer has complied with a regulatory 
agency’s safety requirements for the product, a judge should 
understand precisely what the agency has required and why. This 
is sound advice in general and especially important in the context 
of suits to recover for injuries caused by products regulated by 
FDA. FDA-regulated products account for roughly one quarter of 
the consumer economy, but they are subject to very different types 
and levels of safety regulation. Some products—notably 
therapeutic drugs—are carefully assessed for safety before they are 
marketed and must comply with detailed requirements for design, 
manufacture, labeling, and marketing, which reflect FDA’s 
considered judgment about what precautions are appropriate and 
consistent with the health benefits they provide. And drug 
                                                          
20 The drug combination Phen-fen is not a “dietary supplement.” It may be 
promoted for its effects related to diet, e.g., as a weight-reducing agent, but it 
was marketed with claims that made it, under the law, a drug. Phen-fen therefore 
required the kind of FDA approval used for drugs. 
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manufacturers are under a continuing duty to share with FDA all of 
the information they learn about the effects of their products in use. 
The case for allowing tort recovery—and for imposing an 
additional level of deterrence—is much stronger for cosmetics and 
most foods, which are not required to undergo premarket review 
for safety and thus carry no implication that FDA has assessed and 
attempted to control their risks. Dietary supplements are similarly 
subject only to ex post regulation for safety. The regulatory 
scheme for medical devices is more complicated and a judge 
should be attentive to the different levels of safety review required 
for new devices and for variations of familiar devices. 
FDA-regulated products are frequently the target of liability 
suits because they are universally consumed and because many 
medical products have the capacity to injure as well as the ability 
to cure or prevent injury. The latter are subject to unusual levels of 
regulatory control, a reality that should elicit careful and informed 
judicial assessment. 
 
